The 2026 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Michael Ong discussing TRIPLE-SWITCH (SWOG/CCTG-PR26), a randomized phase III clinical ...
Radiographic progression free survival (RECIST 1.1 and PCWG3) CTCAE v5.0 ...
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial targets ...
Morning Overview on MSN
A daily multivitamin just slowed all five epigenetic aging clocks in a randomized trial — the people who started biologically older showed the biggest benefit
A two-year randomized trial found that a daily multivitamin slowed biological aging across all five epigenetic clocks tested ...
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized ...
The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who ...
A phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 (GSK’227), alone and in combination in patients with previously treated advanced unresectable or ...
Targeted indoor residual spraying focuses insecticide applications on common resting surfaces of Aedes aegypti mosquitoes (an arboviral disease vector) in houses, such as exposed lower sections of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results